Pasireotide versus continued treatment with octreotide or lanreotide in patients with inadequately controlled acromegaly (PAOLA): A randomised, phase 3 trial

The Lancet Diabetes and Endocrinology

Volumn 2, Issue 11, 2014, Pages 875-884

  Gadelha, Mônica R ^a   Bronstein, Marcello D ^b   Brue, Thierry ^c   Coculescu, Mihail ^d   Fleseriu, Maria ^e   Guitelman, Mirtha ^f   Pronin, Vyacheslav ^g   Raverot, Gérald ^h   Shimon, Ilan ⁱ   Lievre, Kayo Kodama ^j   Fleck, Juergen ^j   Aout, Mounir ^j   Pedroncelli, Alberto M ^j   Colao, Annamaria ^k  

^a FEDERAL UNIVERSITY OF RIO DE JANEIRO   (Brazil)

^b UNIVERSITY OF SÃO PAULO   (Brazil)

^c AIX MARSEILLE UNIVERSITY   (France)

^d CAROL DAVILA UNIVERSITY OF MEDICINE AND PHARMACY   (Romania)

^e OREGON HEALTH AND SCIENCE UNIVERSITY   (United States)

^f HOSPITAL DURAND   (Argentina)

^g I M SECHENOV FIRST MOSCOW STATE MEDICAL UNIVERSITY   (Russian Federation)

^h HOSPICES CIVILS DE LYON   (France)

ⁱ TEL AVIV UNIVERSITY   (Israel)

^j NOVARTIS PHARMA AG   (Switzerland)

^k UNIVERSITY OF NAPLES FEDERICO II   (Italy)

more..

Author keywords

[No Author keywords available]

Indexed keywords

ANGIOPEPTIN; GROWTH HORMONE; OCTREOTIDE; PASIREOTIDE; SOMATOMEDIN C; CYCLOPEPTIDE; HUMAN GROWTH HORMONE; SOMATOSTATIN;

ABDOMINAL PAIN; ACROMEGALY; ADULT; AGED; ALOPECIA; ANEMIA; ARTICLE; CHOLELITHIASIS; CONTROLLED STUDY; DIABETES MELLITUS; DIARRHEA; DISEASE CONTROL; DISEASE SEVERITY; DIZZINESS; DRUG DOSE COMPARISON; DRUG EFFICACY; DRUG SAFETY; FEMALE; FIRST DEGREE ATRIOVENTRICULAR BLOCK; HEADACHE; HUMAN; HYPERGLYCEMIA; HYPOGLYCEMIA; IMPAIRED GLUCOSE TOLERANCE; MAJOR CLINICAL STUDY; MALE; MONOTHERAPY; MULTICENTER STUDY; NAUSEA; OUTCOME ASSESSMENT; PARALLEL DESIGN; PHASE 3 CLINICAL TRIAL; PROSPECTIVE STUDY; RANDOMIZED CONTROLLED TRIAL; RHINOPHARYNGITIS; SCREENING; ADOLESCENT; ANALOGS AND DERIVATIVES; BLOOD; CLINICAL TRIAL; MIDDLE AGED; TREATMENT OUTCOME; VERY ELDERLY; YOUNG ADULT;

ACROMEGALY; ADOLESCENT; ADULT; AGED; AGED, 80 AND OVER; FEMALE; HUMAN GROWTH HORMONE; HUMANS; INSULIN-LIKE GROWTH FACTOR I; MALE; MIDDLE AGED; OCTREOTIDE; PEPTIDES, CYCLIC; SOMATOSTATIN; TREATMENT OUTCOME; YOUNG ADULT;

EID: 84922576956     PISSN: 22138587     EISSN: 22138595     Source Type: Journal    
DOI: 10.1016/S2213-8587(14)70169-X     Document Type: Article

References (28)

1. Melmed S Medical progress: acromegaly. N Engl J Med 2006, 355:2558-2573.
2. Giustina A, Chanson P, Kleinberg D, et al. Expert consensus document: a consensus on the medical treatment of acromegaly. Nat Rev Endocrinol 2014, 10:243-248.
3. Chanson P, Borson-Chazot F, Kuhn J-M, Blumberg J, Maisonobe P, Delemer B Control of IGF-I levels with titrated dosing of lanreotide Autogel over 48 weeks in patients with acromegaly. Clin Endocrinol (Oxf) 2008, 69:299-305.
4. Colao A, Cappabianca P, Caron P, et al. Octreotide LAR vs. surgery in newly diagnosed patients with acromegaly: a randomized, open-label, multicentre study. Clin Endocrinol (Oxf) 2009, 70:757-768.
5. Melmed S, Cook D, Schopohl J, Goth MI, Lam KS, Marek J Rapid and sustained reduction of serum growth hormone and insulin-like growth factor-1 in patients with acromegaly receiving lanreotide Autogel therapy: a randomized, placebo-controlled, multicenter study with a 52 week open extension. Pituitary 2010, 13:18-28.
6. Mercado M, Borges F, Bouterfa H, et al. A prospective, multicentre study to investigate the efficacy, safety and tolerability of octreotide LAR (long-acting repeatable octreotide) in the primary therapy of patients with acromegaly. Clin Endocrinol (Oxf) 2007, 66:859-868.
7. Colao A, Auriemma RS, Lombardi G, Pivonello R Resistance to somatostatin analogs in acromegaly. Endocr Rev 2011, 32:247-271.
8. Jallad RS, Musolino NR, Salgado LR, Bronstein MD Treatment of acromegaly with octreotide-LAR: extensive experience in a Brazilian institution. Clin Endocrinol (Oxf) 2005, 63:168-175.
9. Toledano Y, Rot L, Greenman Y, et al. Efficacy of long-term lanreotide treatment in patients with acromegaly. Pituitary 2009, 12:285-293.
10. Colao A, Pivonello R, Auriemma RS, Galdiero M, Savastano S, Lombardi G Beneficial effect of dose escalation of Octreotide-LAR as first-line therapy in patients with acromegaly. Eur J Endocrinol 2007, 157:579-587.
11. Fleseriu M Clinical efficacy and safety results for dose escalation of somatostatin receptor ligands in patients with acromegaly: a literature review. Pituitary 2011, 14:184-193.
12. van der Lely AJ, Biller BM, Brue T, et al. Long-term safety of pegvisomant in patients with acromegaly: comprehensive review of 1288 subjects in ACROSTUDY. J Clin Endocrinol Metab 2012, 97:1589-1597.
13. van der Lely AJ, Hutson RK, Trainer PJ, et al. Long-term treatment of acromegaly with pegvisomant, a growth hormone receptor antagonist. Lancet 2001, 358:1754-1759.
14. Bruns C, Lewis I, Briner U, Meno-Tetang G, Weckbecker G SOM230: a novel somatostatin peptidomimetic with broad somatotropin release inhibiting factor (SRIF) receptor binding and a unique antisecretory profile. Eur J Endocrinol 2002, 146:707-716.
15. Colao A, Bronstein MD, Freda P, et al. Pasireotide versus octreotide in acromegaly: a head-to-head superiority study. J Clin Endocrinol Metab 2014, 99:791-799.
16. Webb SM, Prieto L, Badia X, et al. Acromegaly Quality of Life Questionnaire (ACROQOL) a new health-related quality of life questionnaire for patients with acromegaly: development and psychometric properties. Clin Endocrinol (Oxf) 2002, 57:251-258.
17. Hirji K, Mehta CR, Patel NR Computing distributions for exact logistic regression. J Am Statist Assoc 1987, 82:1110-1117.
18. Bretz F, Maurer W, Brannath W, Posch M A graphical approach to sequentially rejective multiple test procedures. Stat Med 2009, 28:586-604.
19. Maurer W, Glimm E, Bretz F Multiple and repeated testing of primary, coprimary and secondary hypotheses. Statist Biopharm Res 2011, 3:336-352.
20. Wildemberg LE, Neto LV, Costa DF, et al. Low somatostatin receptor subtype 2, but not dopamine receptor subtype 2 expression predicts the lack of biochemical response of somatotropinomas to treatment with somatostatin analogs. J Endocrinol Invest 2013, 36:38-43.
21. Van Der Hoek J, de Herder WW, Feelders RA, et al. A single-dose comparison of the acute effects between the new somatostatin analog SOM230 and octreotide in acromegalic patients. J Clin Endocrinol Metab 2004, 89:638-645.
22. Henry RR, Ciaraldi TP, Armstrong D, Burke P, Ligueros-Saylan M, Mudaliar S Hyperglycemia associated with pasireotide: results from a mechanistic study in healthy volunteers. J Clin Endocrinol Metab 2013, 98:3446-3453.
23. Colao A, De Block C, Gaztambide MS, Kumar S, Seufert J, Casanueva FF Managing hyperglycemia in patients with Cushing's disease treated with pasireotide: medical expert recommendations. Pituitary 2014, 17:180-186.
24. Petersenn S, Schopohl J, Barkan A, et al. Pasireotide (SOM230) demonstrates efficacy and safety in patients with acromegaly: a randomized, multicenter, phase II trial. J Clin Endocrinol Metab 2010, 95:2781-2789.
25. Petersenn S, Bollerslev J, Arafat AM, et al. Pasireotide LAR shows efficacy in patients with acromegaly: interim results from a randomized, multicenter, pharmacokinetic, pharmacodynamic, phase I study. 90th Annual Meeting of The Endocrine Society; San Francisco, CA, USA; June 15-18, 2008. Abstr OR41-5.
26. Cozzi R, Attanasio R, Montini M, et al. Four-year treatment with octreotide-long-acting repeatable in 110 acromegalic patients: predictive value of short-term results?. J Clin Endocrinol Metab 2003, 88:3090-3098.
27. Caron P, Cogne M, Raingeard I, Bex-Bachellerie V, Kuhn JM Effectiveness and tolerability of 3-year lanreotide Autogel treatment in patients with acromegaly. Clin Endocrinol (Oxf) 2006, 64:209-214.
28. Colao A, Pivonello R, Rosato F, et al. First-line octreotide-LAR therapy induces tumor shrinkage and controls hormone excess in patients with acromegaly: results from an open, prospective, multicentre trial. Clin Endocrinol (Oxf) 2006, 64:342-351.